Press Release

October 11, 2021
1 min read

Dextenza receives FDA approval for ocular itching associated with allergic conjunctivitis


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The FDA has approved a supplemental new drug application for Dextenza, adding ocular itching associated with allergic conjunctivitis to the drug’s current indications, according to a press release from Ocular Therapeutix.

“Allergic conjunctivitis is a common condition seen in the offices of eye care providers. We are really excited about this label expansion and the potential benefits for patients,” Michael Goldstein, MD, president, ophthalmology, and chief medical officer at Ocular Therapeutix, said in the release.

Source: Adobe Stock

The new approval for Dextenza (dexamethasone ophthalmic insert 0.4 mg) is based on three randomized, multicenter, double-masked, parallel-group, vehicle-controlled studies that demonstrated lower mean ocular itching scores with Dextenza vs. vehicle at all time points throughout the study up to 30 days. In addition, the insert had a “favorable” safety profile.

Dextenza previously received FDA approval in 2018 for the treatment of ocular pain following ophthalmic surgery, with a label expansion to include the treatment of ocular inflammation following ophthalmic surgery in 2019.